On February 14, 2024, ENDRA Life Sciences Inc. made an exciting announcement regarding the issuance of three new patents for their Thermo Acoustic Enhanced UltraSound (TAEUS®) system. These patents are crucial for enhancing the capabilities of the TAEUS system and improving various aspects of its functionality.
The first patent, U.S. Patent No. 11844650 (the ‘650 patent), focuses on a unique sleeve-type structural configuration for the TAEUS system. This configuration maximizes the absorption of radiofrequency energy and subsequently enhances the strength of the thermoacoustic signal. Additionally, it minimizes signal noise, resulting in a clearer and more precise thermoacoustic signal. The ‘650 patent also introduces a plurality of radiofrequency feeds that enable signal polarization, further improving the accuracy of thermoacoustic measurements.
The second patent, Chinese Patent No. ZL2021800757024 (the ‘024 patent), is titled “Thermal Ablation System with Integrated Thermoacoustic Temperature Measurement.” This patent is particularly significant as it focuses on the TAEUS system’s ability to determine temperature at specific locations within the human body. By monitoring temperature during thermal ablation procedures, this system ensures that overheating is avoided, preventing damage to healthy tissue. Furthermore, it also prevents underheating, which is crucial for effectively destroying targeted cancerous tumor cells.
The third patent, European Patent No. EP3902490, titled “Method and System for Monitoring Tissue Temperature,” introduces a novel method for monitoring tissue temperature during surgical procedures using the TAEUS system. This method can be applied to various surgical procedures, including thermotherapy and cryotherapy, providing surgeons with real-time temperature monitoring capabilities. By ensuring precise temperature control, this patent enhances the safety and effectiveness of these surgical interventions.
With the issuance of these three new patents, ENDRA Life Sciences’ intellectual property portfolio now consists of a total of 74 patents. This significant expansion reaffirms the company’s dedication to advancing state-of-the-art thermoacoustic systems and addressing unmet clinical needs through their innovative TAEUS® technology.
NDRA Stock Price Fluctuations on February 14, 2024: Mixed Performance and Investment Considerations
On February 14, 2024, the stock of ENDRA Life Sciences Inc. (NDRA) showcased some interesting price movements. NDRA was observed to be trading near the bottom of its 52-week range on February 14, 2024. Additionally, NDRA was trading below its 200-day simple moving average. The price of NDRA shares experienced a modest increase of $0.01 since the market last closed on February 14, 2024, resulting in a rise of 1.11% from its previous closing price. However, the positive momentum did not continue into after-hours trading, as the stock price dropped by $0.03 during this period, signifying a decrease of 2.73% from its closing price. These fluctuations in NDRA’s stock price indicate a mixed performance on February 14, 2024. NDRA Life Sciences Inc. is a company that specializes in the development and commercialization of medical imaging technologies. It is important to conduct thorough research and analysis before making any investment decisions. Please note that the information provided in this article is based on data sourced from CNN Money.
Analyzing NDRA Stock Performances on February 14, 2024: A Closer Look at the Numbers – Net Income Declines, Earnings per Share Show Mixed Results
Title: Analyzing NDRA Stock Performances on February 14, 2024: A Closer Look at the Numbers
Introduction
On February 14, 2024, investors closely monitored the stock performance of NDRA (company name unavailable) as they sought to assess the company’s financial health and potential for growth. In this article, we will analyze key financial indicators such as net income and earnings per share to gain insights into the company’s financial position.
Net Income: A Declining Trend
NDRA reported a net income of -$13.18 million over the past year, which represents a 17.34% decrease compared to the previous year. Furthermore, in the most recent quarter, NDRA’s net income stood at -$3.10 million, reflecting a 21.26% decrease compared to the previous quarter.
Earnings per Share: Mixed Results
NDRA reported an EPS of -$4.56 over the past year, representing a 17.84% increase compared to the previous year. In the most recent quarter, NDRA’s EPS stood at -$0.40, reflecting a 5.39% increase compared to the previous quarter.
Implications and Conclusion
The available financial data for NDRA on February 14, 2024, paints a mixed picture of the company’s performance. While the net income has experienced a decline both in the long and short term, the EPS has shown growth, albeit from a negative base.
It is crucial to consider additional factors and obtain more comprehensive data to gain a holistic understanding of NDRA’s financial performance. Investors should closely monitor future financial reports to assess if the company can reverse the negative trends and achieve sustainable profitability.
As with any investment, it is recommended that investors conduct thorough research, consider risk factors, and consult with financial professionals before making any investment decisions related to NDRA or any other stock.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice.
